Population-based study of influenza and invasive meningococcal disease among Greek children during the COVID-19 pandemic

Danai Ktena 1, Eleni Kourkouni,2 Flora Kontopidou,3 Kassiani Gkolfinopoulou,4 Kalliopi Papadima,5 Theano Georgakopoulou,6 Ioanna Magaziotou,8 Anastasia Andreopoulou,5 Georgina Tzanakaki,7 Theoikis Zaoutis,8,9 Vassiliki Papaevangelou1

ABSTRACT

Background Aiming to the containment of the coronavirus disease 2019 (COVID-19) pandemic, governments worldwide have implemented a series of non-pharmaceutical interventions. Many of them and especially school closures have impacted the circulation of multiple airborne pathogens among children and adolescents. This study investigates the incidence of influenza and invasive meningococcal disease among children aged 0–14 years in Greece during the COVID-19 pandemic.

Methods Data regarding the number of influenza-like illness cases, influenza-related paediatric intensive care unit (PICU) admissions and invasive meningococcal disease cases among children 0–14 years old were obtained from the National Public Health Organization. The incidence of the two diseases during the COVID-19 pandemic period (2020/2021) was compared with that of the six preceding seasons (2014–2019).

Results A notable decrease was observed in both influenza and invasive meningococcal disease cases during the period 2020/2021 compared with the years 2014–2019. The mean annual rate of influenza-like illness cases and influenza-related PICU admissions in children 0–14 years old has reduced by 66.9% and 100%, respectively, while the mean annual invasive meningococcal disease rate has declined by 70%.

Both weekly influenza-like illness and monthly invasive meningococcal disease rates were significantly decreased.

Conclusions The activity of influenza and invasive meningococcal disease in the children and adolescents of Greece has decreased during the COVID-19 pandemic period. Reduced transmission is likely related to the public health measures that were implemented to control the pandemic. The value of these measures may have relevance to the future management of influenza or invasive meningococcal disease epidemics.

INTRODUCTION

In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, which causes coronavirus disease 2019 (COVID-19), emerged in Wuhan, China.1 The disease spread rapidly and on 11 March 2020 WHO declared a COVID-19 pandemic.2 Since then, more than 435 million confirmed cases have been reported globally, 2 million of which in Greece.3 COVID-19 is transmitted from person to person mainly via respiratory droplets, including aerosols, as well as direct contact.4 To contain viral transmission a series of non-pharmaceutical public health measures, such as social distancing, use of face masks, promotion of increased hand hygiene, lockdown, curfew, school closures, isolation of confirmed cases and quarantine of exposed subjects, have been
implemented since March 2020. Due to their broad implementation, these measures potentially impact the transmission of other infectious diseases that spread via the respiratory route as well.

Seasonal influenza is a common cause of respiratory disease, linked to increased rates of hospitalisations, in both children and adults. Influenza virus is transmitted via respiratory droplets, aerosols and through contact with infected individuals or contaminated fomites. In temperate regions, epidemics occur every winter and are associated with increased morbidity and mortality. The expected influenza peak during the winter months of 2020 and the co-circulation with SARS-CoV-2 caused worldwide concern, regarding the consequential overwhelming of healthcare systems and therefore campaigns promoting influenza vaccination, both among adults and children, were held in many countries. In Greece, influenza vaccination for children according to the National Immunization Program (NIP), is recommended only for those at high risk. However, the incidence of influenza during the endemic periods of both 2019–2020 and 2020–2021 remained notably low, not only in Europe, but also globally.

Considering then, the known role of influenza infection as a risk factor for invasive meningococcal disease (IMD), one may postulate a concomitant decrease of the IMD incidence during the COVID-19 pandemic. IMD usually presents as meningitis or septicaemia and mainly affects children younger than 2 years old and adolescents. It is caused by Neisseria meningitidis, which is transmitted from person to person through respiratory droplets from infected patients or carriers. The rate of N. meningitidis asymptomatic carriage shows an increasing trend through childhood from 4.5% in infants to a peak of 23.7% in 19-year-olds and gradually decreases in older adults. Even though IMD incidence in developed countries has remained low during the last few years, mainly due to the implementation of universal infant vaccination, its epidemiology is often unpredictable and characterised by changes in incidence and prevalent serogroups. In Greece, the NIP includes MenC immunisation at 12 months of age since 2006 and MenACWY quadrivalent conjugated immunisation in 11 years old adolescents since 2012. Moreover, MenB vaccine has been available in the private market since 2014 but is not included in the NIP. Studies have already shown a decrease in the incidence of IMD during the COVID-19 pandemic.

The non-pharmaceutical measures that have been used to contain the COVID-19 pandemic differ from country to country, while different age groups have been impacted in various ways. School closures, for example, have probably had a significant effect on the incidence of other infectious diseases in children. Taking into consideration the burden of both diseases on the paediatric population, as well as the important role of this age group in community transmission, this study aimed to investigate the incidence of influenza and IMD in Greek children and adolescents aged 0–14 years during the COVID-19 pandemic.

MATERIALS AND METHODS

The surveillance of influenza in Greece is carried out using several systems. The Morbidity Monitoring System in Primary Healthcare (Sentinel) uses weekly reports from an established collaborating primary care unit network. Surveillance systems also include laboratory surveillance and surveillance of severe influenza cases in intensive care unit. Data are collected and published in the form of weekly reports by the National Public Health Organization (NPHO). These systems are active during the influenza surveillance period, from week 40 (October) of every year to week 20 (May) of the following year. Bacterial meningitis is a mandatory notifiable disease in Greece and all registered cases are investigated and classified by causative agent. IMD samples from hospitals nationwide are sent and identified at the National Meningitis Reference Laboratory. Confirmed cases are reported to NPHO.

For this population-based observational study, in collaboration with the NPHO, we collected data regarding weekly influenza-like illness (ILI) cases and annual influenza-related paediatric intensive care unit (PICU) admissions for influenza seasons 2014/2015–2020/2021 and monthly IMD cases from January 2014 until May 2021 among children aged 0–14 years. The data were stratified by age group (0–4, 5–14 years). To calculate incidence rates, we used the number of visits to the Sentinel Primary Healthcare units for children aged 0–14 years and each age group separately, as well as the population of children 0–14, 0–4 and 5–14 years old, according to the 2011 census data. Data from the COVID-19 pandemic period (2020–2021) were compared with that of the six preceding pre-COVID-period years (2014/2015–2019/2020). Influenza seasons and annual IMD cases were compared in total and by age group. Additional sensitivity analysis was performed to include IMD data from 2009, in order to examine the potential impact of the introduction of the Meningococcus serotype B vaccine in 2014.

Incidence rates were calculated for influenza as ILI cases per 1000 visits and influenza-related PICU admissions per 100 000 population and for IMD as cases per 100 000 population. Descriptive statistics of rates are presented with median and IQR. Percentage of decrease in the mean of annual rates over the two periods 2014–2020 versus 2021 was also calculated. Run charts were used to graphically represent the annual, monthly or weekly rates across time. Interrupted time series analysis was also performed to assess any changes in IMD trends. No statistical inference was made since the data used cover the study population.
Patient and public involvement
Authors declare that there was no patient or public involvement in the present study.

RESULTS
Influenza
The mean of weekly ILI rates per 1000 visits for children aged 0–14 years was notably lower during the season 2020/2021 compared with the preceding periods (2014/2015–2019/2020) (rates 88.2 vs 23.1, figure 1).

A reduction of 66.9% has been noted in the mean annual rate of ILI cases per 1000 visits among children younger than 14 years old, which has decreased from 102.9 during the pre-COVID-19 period (2014/2015–2019/2020) to 34.0 during 2020/2021. The decrease in the mean annual rate was 58.5% and 71.8% for ages 0–4 and 5–14, respectively (online supplemental figure S1).

Finally, no influenza-related PICU admissions were recorded in children aged 0–14 years during the period 2020/2021. The mean annual rate of laboratory-confirmed influenza cases in PICU per 100,000 population declined by 100%, from 1.06 during the period 2014/2015–2019/2020 to 0.00 (figure 2).

Figure 1  ILI weekly rates per 1000 visits during the influenza surveillance period 2020/2021 compared with minimum, mean and maximum of previous seasons (2014/2015–2019/2020) for children 0–14 years old. ILI, influenza-like illness.

Figure 2  Annual rates of laboratory-confirmed influenza cases in PICU per 100,000 population (2014/2015–2020/2021), stratified by age group. PICU, paediatric intensive care unit.
The mean annual rate of IMD cases per 100,000 children aged 0–14 during the period 2014–2019 was 1.38. A significant decrease of 70% was observed during 2020–2021 yielding a mean annual incidence of 0.41. More specifically, the decrease in the mean annual rate was 67% and 76% for ages 0–4 and 5–14, respectively (online supplemental figure S2).

Descriptive statistics of monthly IMD rates per 100,000 population are presented in table 1. The median of monthly incidence rates of the period March 2020–May 2021 was 0.02, which is considerably lower than the one of the period from January 2014 to February 2020 (0.10). IMD monthly rates during the period 2020–2021 compared with the monthly rates of the years 2014–2019 are shown in figure 3. On applying interrupted time series analysis there was no change in the trend between the periods 2014–2019 and 2020–2021. In order to examine the potential impact of MenB immunisation after 2014, the analysis was repeated using data from 2009. A consistent trend of decrease was observed throughout the examined period, with no significant trend change (figure 4).

### DISCUSSION

Influenza and IMD represent important vaccine-preventable diseases with a high disease burden in children aged under 15 years. The incidence of both diseases has shown notable reduction, mainly among adults so far, following the implementation of COVID-19 restrictions, not only in Europe but also worldwide. In this study, a significant decline was observed in the number of recorded ILI and influenza-related PICU cases, as well as confirmed IMD cases among children 0–14 years old during the period 2020–2021 compared with previous years (2014–2019). As in many countries, influenza remained at an all-time low in Greece during the period 2020/2021, while no circulation of influenza was detected this past winter. A considerable decrease was also observed in the incidence of IMD since March 2020, although there was no significant change in the trend. IMD cases in Greece have been steadily declining since 2013, coinciding with the introduction of the MenB vaccine in March 2014. Interestingly, the number of MenB vaccinations has also declined since March 2020 (data not shown), suggesting that they might not have contributed to the excess reduction of IMD cases during

<table>
<thead>
<tr>
<th>Period</th>
<th>Number of months</th>
<th>Median of monthly IMD rates per 100 000 population (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ages 0–14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>January 2014–February 2020</td>
<td>73</td>
<td>0.10 (0.05–0.15)</td>
</tr>
<tr>
<td>March 2020–May 2021</td>
<td>16</td>
<td>0.02 (0.00–0.05)</td>
</tr>
<tr>
<td>Ages 0–4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>January 2014–February 2020</td>
<td>73</td>
<td>0.19 (0.00–0.37)</td>
</tr>
<tr>
<td>March 2020–May 2021</td>
<td>16</td>
<td>0.00 (0.00–0.19)</td>
</tr>
<tr>
<td>Ages 5–14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>January 2014–February 2020</td>
<td>73</td>
<td>0.00 (0.00–0.10)</td>
</tr>
<tr>
<td>March 2020–May 2021</td>
<td>16</td>
<td>0.00 (0.00–0.00)</td>
</tr>
</tbody>
</table>

IMD, invasive meningococcal disease.

**Table 1** Summary statistics of monthly IMD rates per 100,000 population.
Another contributing factor to the observed decline of the number of influenza cases could be the reduction of healthcare utilisation. The number of visits of both age groups reported by the Sentinel surveillance system has in fact decreased during the period 2020/2021. However, the ILI rates per 1000 visits have also declined notably, showing that the decreased number of reported cases reflects an actual lack of infections. As far as IMD is concerned, due to the severity of the disease, healthcare-seeking behaviour is unlikely to be affected by the pandemic.

The possibility of an influenza pandemic, as well as the unpredictable epidemiology of IMD, highlight the importance of these findings. Given the concerns that the influenza season would coincide with the pandemic or that COVID-19—like other viral infections—could be linked with an increase in IMD cases, the reduced incidence of both diseases has been reassuring. However, due to the low circulation of respiratory pathogens, population susceptibility has possibly increased over the past months and thus some researchers predict large outbreaks in the near future with possible shift of the usual seasonality of viral infections. This becomes more evident by the unexpected resurgence of Respiratory Syncytial Virus (RSV) after its initial decline during the COVID-19 pandemic. The upcoming 2021–2022 endemic period remains unknown and will possibly be influenced by the burden of COVID-19 and the extent of NPI use. Nonetheless, influenza immunisation is highly recommended this coming autumn in the Northern hemisphere. Although the very low previous influenza season in 2020–2021 may have impacted the identification of emerging circulating strains endangering the influenza vaccine effectiveness, it is important to stress that vaccination is the most effective way to reduce the influenza-related disease burden. At the same time, the knowledge gained by the COVID-19 pandemic regarding the value of specific NPIs in the control of respiratory pathogens’ transmission is a powerful tool for future prevention and management of both influenza and IMD, especially for high-risk populations.

A strength of this study is that the data used were derived from a nationwide surveillance system that existed before the emergence of COVID-19, allowing reliable comparisons between the different periods. Furthermore, our study focuses on the impact that COVID-19 restrictions had on the incidence of influenza and IMD specifically in the paediatric population, which is particularly affected by both diseases, in terms of transmission as well as morbidity.

However, there are several limitations that need to be acknowledged. There is lack of data regarding laboratory-confirmed influenza cases and consequently information on prevalent types and subtypes. Laboratory surveillance data of influenza in Greece are collected solely by the two National Reference Laboratories, which are not necessarily representative of the total number of influenza tests that are conducted. Secondly, due to the ecological
nature of this study, causality between the interventions and the decreased incidence of the two diseases cannot be determined. However, temporal association and biological plausibility make it a compelling hypothesis. Finally, the Sentinel data used in this study were based on clinicians' reports. It is, therefore, possible that the number of influenza cases is underestimated due to lower disease reporting rates during the pandemic.

To conclude, maintaining the wide use of NPIs has shown to be effective in mitigating the transmission of respiratory agents in the community. Nevertheless, the dynamics of infectious diseases remain ever-changing and it is vital that we remain vigilant. Therefore, ongoing surveillance, as well as vaccinations, are of great importance in order to reduce the burden of influenza and IMD on the already overwhelmed healthcare systems.

**Author affiliations**
1 Third Department of Pediatrics, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Attica, Greece
2 Centre for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece
3 Department of Healthcare-Associated Infections and Antimicrobial Resistance, Directorate of Epidemiological Surveillance and Intervention for Infectious Diseases, National Public Health Organization, Athens, Greece
4 Department of Surveillance Systems, Directorate of Epidemiological Surveillance and Interventions for Infectious Diseases, National Public Health Organization, Athens, Greece
5 Department of Respiratory Diseases, Directorate of Epidemiological Surveillance and Interventions for Infectious Diseases, National Public Health Organization, Athens, Greece
6 Department of Vaccine Preventable Diseases and Congenital Diseases, Directorate of Epidemiological Surveillance and Interventions for Infectious Diseases, National Public Health Organization, Athens, Greece
7 National Meningitis Reference Laboratory, Department of Public Health Policy, University of West Attica, Athens, Greece
8 Second Department of Pediatrics, P&A Kyriakou Children’s Hospital, National and Kapodistrian University of Athens, Athens, Attica, Greece
9 National Public Health Organization, Athens, Greece

**Acknowledgements** We would like to thank Panagiotis Katerelos for editing and organising the influenza Sentinel data and Dimitra Kousi for assisting in the statistical analysis.

**Contributors** DK participated in the conceptualisation and design of the study; contributed to data interpretation and writing, reviewing and editing of the manuscript. EK participated in the statistical analysis; contributed to the interpretation of the analysis and reviewing and editing of the manuscript. FK, KG, KP, TG, IM, AA and GT participated in the acquisition and interpretation of data; contributed to reviewing and editing of the manuscript. TZ participated in the conceptualisation and design of the study; contributed to the interpretation of the statistical analysis and reviewing and editing of the manuscript. VP is the guarantor for this study and participated in the conceptualisation and design, supervision and project administration; contributed to data interpretation and writing, reviewing and editing of the manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not applicable.

**Ethics approval** This study does not involve human participants.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. Aggregate data may be available on request to the corresponding author and after approval by the NPHO.

---

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the original work is not commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD** Danai Ktena http://orcid.org/0000-0002-0952-8915

**REFERENCES**

33 Hussain F, Kotecha S, Edwards MO. RSV bronchiolitis season 2021 has arrived, so be prepared! Arch Dis Child 2021;106:e61.